Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Alimera Sciences

NASDAQ ALIM
$3.28 -0.20 -6.10%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 22 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

178.51M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
231.73M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.72
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
54.42M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-24.07 %

Upcoming events Alimera Sciences

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Alimera Sciences

Stock analysis Alimera Sciences

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-7.61 8.79
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
3.87 25.38
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
31.85 4.40
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
7.32 0.50
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-50.82 9.54

Price change Alimera Sciences per year

3.82$ 12.25$
Min Max

Summary analysis Alimera Sciences

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Alimera Sciences

Revenue and net income Alimera Sciences

All parameters

Stock news Alimera Sciences

All news
2 January в 16:30

Alimera Sciences Names Elliot Maltz Chief Financial Officer

2 January в 16:30

Alimera Sciences Names Elliot Maltz Chief Financial Officer

12 June 2023 в 15:00

Alimera Sciences upgraded to buy from neutral at Alliance Global

18 May 2023 в 17:50

Alimera Sciences Shares Rise 22% After Buying U.S. Yutiq Rights From EyePoint

18 May 2023 в 17:50

Alimera Sciences Shares Rise 22% After Buying U.S. Yutiq Rights From EyePoint

18 May 2023 в 14:40

Alimera Sciences Buys U.S. Commercial Rights to Chronic Uveitis Treatment Yutiq

18 May 2023 в 14:40

Alimera Sciences Buys U.S. Commercial Rights to Chronic Uveitis Treatment Yutiq

27 March 2023 в 17:41

Alimera Sciences Shares Rise 18% After Capital Restructuring

27 March 2023 в 17:41

Alimera Sciences Shares Rise 18% After Capital Restructuring

13 October 2021 в 20:25

Alimera Sciences Shares Rise 7% After Positive Data for Iluvien Trial

13 October 2021 в 20:20

Alimera Sciences Shares Rise 7% After Positive Data for Iluvien Trial

About company Alimera Sciences

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Address:
6120 Windward Parkway, Alpharetta, GA, United States, 30005
Company name: Alimera Sciences
Issuer ticker: ALIM
ISIN: US0162592028
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2010-04-22
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.alimerasciences.com

On which stock exchange are Alimera Sciences (ALIM) stocks traded?

Alimera Sciences (ALIM) stocks are traded on NASDAQ.

What is the ticker of Alimera Sciences stocks (ALIM)?

The stock ticker of Alimera Sciences’s stocks or in other words, the code is ALIM. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Alimera Sciences (ALIM) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Alimera Sciences (ALIM) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are Alimera Sciences (ALIM) stocks traded?

Alimera Sciences (ALIM) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Alimera Sciences (ALIM) stocks today?

The current price of Alimera Sciences stocks on 15.05.2024 is 3.28 dollars. per share.

What is the dynamics of Alimera Sciences (ALIM) stocks from the beginning of the year?

Alimera Sciences (ALIM) quotes have increased by -19.61% from the beginning of the year up to 3.28 dollars. per 1 stocks.

How much did Alimera Sciences (ALIM) stocks increase in мае 2024?

This month Alimera Sciences (ALIM) quotes have increased by -5.2% to 3.28 dollars. per share.

How much are Alimera Sciences (ALIM) stocks worth?

Today, on October, 15.05.2024 Alimera Sciences’s (ALIM) stocks cost 3.28 dollars..

What is the market capitalization of Alimera Sciences (ALIM)?

Capitalization is the market value of Alimera Sciences (ALIM) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 15.05.2024, the market capitalization of Alimera Sciences (ALIM) is estimated at about 178507325 dollars.